Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - cotellic
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp3a2e83e300727740331b28eb7f2593e4
identifier: http://ema.europa.eu/identifier
/EU/1/15/1048/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Cotellic 20 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-3a2e83e300727740331b28eb7f2593e4
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/15/1048/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - cotellic
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet:
What Cotellic is Cotellic is an anti-cancer medicine that contains the active substance cobimetinib.
What Cotellic is used for Cotellic is used to treat adult patients with a type of skin cancer called melanoma, that has spread to other parts of the body or cannot be removed by surgery.
How Cotellic works Cotellic targets a protein called MEK that is important in controlling cancer cell growth. When Cotellic is used in combination with vemurafenib (which targets the changed BRAF protein), it further slows down or stops the growth of your cancer.
Do not take Cotellic:
Warnings and precautions Talk to your doctor, pharmacist or nurse before taking Cotellic if you have:
Bleeding Cotellic can cause severe bleeding, especially in your brain or stomach (see also Severe bleeding in Section 4). Tell your doctor straight away if you have any unusual bleeding or any of these symptoms: headaches, dizziness, feeling weak, blood in the stools or black stools and vomiting blood.
Eye problems Cotellic can cause eye problems (see also Eye (vision) problems in Section 4). Tell your doctor straight away if you get the following symptoms: blurred vision, distorted vision, partly missing vision, or any other changes to your sight during treatment. Your doctor should examine your eyes if you have any new or worsening problems with your sight while you are taking Cotellic.
Heart problems Cotellic can lower the amount of blood pumped by your heart (see also Heart problems in Section 4). Your doctor should do tests before and during your treatment with Cotellic to check how well your heart can pump blood. Tell your doctor straight away if it feels like your heart is pounding, racing or beating unevenly, or if you experience dizziness, lightheadedness, shortness of breath, tiredness, or swelling in the legs.
Liver problems Cotellic can increase the amount of some liver enzymes in your blood during treatment. Your doctor will do blood tests to check these amounts and monitor how well your liver is working.
Muscle problems Cotellic can cause increased levels of creatine phosphokinase, an enzyme that is found mainly in the muscle, heart, and brain. This can be a sign of muscle damage (rhabdomyolysis) (see also Muscle problems in Section 4). Your doctor will do blood tests to monitor for this. Tell your doctor straight away if you get any of these symptoms: muscle aches, muscle spasms, weakness, or dark- or red- coloured urine.
Diarrhoea Tell your doctor straight away if you get diarrhoea. Severe diarrhoea can cause loss of body fluid (dehydration). Follow your doctor s instructions for what to do to help prevent or treat diarrhoea.
Children and adolescents Cotellic is not recommended for children and adolescents. The safety and efficacy of Cotellic in people younger than 18 years old have not been established.
Other medicines and Cotellic Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because Cotellic can affect the way some other medicines work. Also, some other medicines can affect the way Cotellic works.
Talk to your doctor before taking Cotellic if you are taking:
Medicine
Purpose of the medicine itraconazole, clarithromycin, erythromycin, telithromycin, voriconazole, rifampicin, posaconazole, fluconazole, miconazole for some fungal and bacterial infections ritonavir, cobicistat, lopinavir, delavirdine, amprenavir, fosamprenavir
for HIV infection telaprevir for hepatitis C nefadozone for depression amiodarone for an uneven heartbeat diltiazem, verapamil for high blood pressure
imatinib for cancer carbamazepine, phenytoin for fits (seizures) St John s Wort a herbal medicine, used to treat depression. This is available without prescription.
Cotellic with food and drink Avoid taking Cotellic with grapefruit juice. This is because it could increase the amount of Cotellic in your blood.
Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you might be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Contraception Women of childbearing potential should use two effective methods of contraception, such as a condom or other barrier method (with spermicide, if available) during treatment and for at least 3 months after treatment has finished. Ask your doctor about the best contraception for you.
Driving and using machines Cotellic can affect your ability to drive or use machines. Avoid driving or using machines if you have problems with your vision or other problems that might affect your ability e.g. if you feel dizzy or tired. Talk to your doctor if you are not sure.
Cotellic contains lactose and sodium The tablets contain lactose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking this medicine.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
How much to take The recommended dose is 3 tablets (a total of 60 mg) once a day.
Taking the medicine
If you are sick If you are sick (vomit) after taking Cotellic, do not take an extra dose of Cotellic on that day. Continue to take Cotellic as normal, the next day.
If you take more Cotellic than you should If you take more Cotellic than you should, talk to a doctor straight away. Take the medicine package and this leaflet with you.
If you forget to take Cotellic
If you stop taking Cotellic It is important to keep taking Cotellic for as long as your doctor prescribes it.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them. If you get side effects your doctor may decide to lower your dose, stop treatment temporarily or permanently.
Please also refer to the Package Leaflet for vemurafenib, which is used in combination with Cotellic.
Serious side effects Tell your doctor straight away if you notice any of the side effects listed below or if these get worse during treatment.
Severe bleeding (common: may affect up to 1 in 10 people) Cotellic can cause severe bleeding, especially in your brain or stomach. Depending on the area of the bleeding, symptoms may include:
Eye (vision) problems (very common: may affect more than 1 in 10 people) Cotellic can cause eye problems. Some of these eye problems may be a result of serous retinopathy
(a build-up of fluid under the retina in the eye). Symptoms of serous retinopathy include:
Heart problems (common: may affect up to 1 in 10 people) Cotellic can lower the amount of blood pumped by your heart. Symptoms may include:
Muscle problems (uncommon: may affect up to 1 in 100 people) Cotellic can result in the breakdown of muscle (rhabdomyolysis), symptoms may include:
Diarrhoea (very common: may affect more than 1 in 10 people) Tell your doctor straight away if you get diarrhoea and follow your doctor s instructions for what to do to help prevent or treat diarrhoea.
Other side effects Tell your doctor, pharmacist or nurse if you notice any of the following side effects:
Very common (may affect more than 1 in 10 people)
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
What Cotellic contains
What Cotellic looks like and contents of the pack Cotellic film-coated tablets are white, round with COB debossed on one side. One pack size is available: 63 tablets (3 blisters of 21 tablets).
Marketing Authorisation Holder Roche Registration GmbH
Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen Germany
Manufacturer Roche Pharma AG Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen Germany
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.
Belgi /Belgique/Belgien
N.V. Roche S.A.
T l/Tel: +32 (0) 2 525 82 Lietuva
UAB Roche Lietuva
Tel: +370 5 2546
: +359 2 818 44 Luxembourg/Luxemburg
(Voir/siehe Belgique/Belgien)
esk republika
Roche s. r. o.
Tel: +420 - 2 20382Magyarorsz g
Roche (Magyarorsz g) Kft.
Tel: +36 - 1 279 4Danmark
Roche Pharmaceutical A/S
Tlf: +45 - 36 39 99 Malta
(see Ireland)
Deutschland
Roche Pharma AG
Tel: +49 (0) 7624 Nederland
Roche Nederland B.V.
Tel: +31 (0) 348 438Eesti
Roche Eesti O
Tel: + 372 - 6 177 Norge
Roche Norge AS
Tlf: +47 - 22 78 90
Roche (Hellas) A.E.
: +30 210 61 66 sterreich
Roche Austria GmbH
Tel: +43 (0) 1 27Espa a
Roche Farma S.A.
Tel: +34 - 91 324 81 Polska
Roche Polska Sp.z o.o.
Tel: +48 - 22 345 18 France
Roche
T l: +33 (0) 1 47 61 40 Portugal
Roche Farmac utica Qu mica, Lda
Tel: +351 - 21 425 70 Hrvatska
Roche d.o.o.
Tel: +385 1 4722 Rom nia
Roche Rom nia S.R.L.
Tel: +40 21 206 47 Ireland
Roche Products (Ireland) Ltd.
Tel: +353 (0) 1 469 0Slovenija
Roche farmacevtska dru ba d.o.o.
Tel: +386 - 1 360 26 sland
Roche Pharmaceuticals A/S
c/o Icepharma hf
S mi: +354 540 8Slovensk republika
Roche Slovensko, s.r.o.
Tel: +421 - 2 52638Italia
Roche S.p.A.
Tel: +39 - 039 2Suomi/Finland
Roche Oy
Puh/Tel: +358 (0) 10 554 K
. . & .
: +357 - 22 76 62 Sverige
Roche AB
Tel: +46 (0) 8 726 1Latvija
Roche Latvija SIA
Tel: +371 - 6 7039United Kingdom (Northern Ireland)
Roche Products (Ireland) Ltd.
Tel: +44 (0) 1707 366This leaflet was last revised in {MM/YYYY}
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-3a2e83e300727740331b28eb7f2593e4
Resource Composition:
Generated Narrative: Composition composition-en-3a2e83e300727740331b28eb7f2593e4
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/15/1048/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - cotellic
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp3a2e83e300727740331b28eb7f2593e4
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp3a2e83e300727740331b28eb7f2593e4
identifier:
http://ema.europa.eu/identifier
/EU/1/15/1048/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Cotellic 20 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en